Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
about
Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic ReviewThe efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisCorrection: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1α/ICAM-1 signaling pathway.
P2860
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Challenges in developing a val ...... tors: the motesanib experience
@ast
Challenges in developing a val ...... tors: the motesanib experience
@en
Challenges in developing a val ...... tors: the motesanib experience
@nl
type
label
Challenges in developing a val ...... tors: the motesanib experience
@ast
Challenges in developing a val ...... tors: the motesanib experience
@en
Challenges in developing a val ...... tors: the motesanib experience
@nl
prefLabel
Challenges in developing a val ...... tors: the motesanib experience
@ast
Challenges in developing a val ...... tors: the motesanib experience
@en
Challenges in developing a val ...... tors: the motesanib experience
@nl
P2093
P2860
P1433
P1476
Challenges in developing a val ...... tors: the motesanib experience
@en
P2093
Barbara A Kaesdorf
Gerard J Davis
Michael B Bass
Michael T Davis
Sabrina S Chan
Scott D Patterson
Yong-Jiang Hei
P2860
P304
P356
10.1371/JOURNAL.PONE.0108048
P407
P577
2014-10-14T00:00:00Z